Ana Sánchez-Pitiot

Ana Sánchez-Pitiot

Auto-generated profile, based on publicly available information

Ana Sánchez-Pitiot

Laboratorio de Oncología Molecular, Laboratorio de Medicina Hospital Universitario Central de Asturias Oviedo Spain

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2003 in Nature Genetics
Verified
Journal Article
Closed access
MBMilagros Balbín
Milagros Balbín
AFAntonio Fueyo
Antonio Fueyo
ATAngus M Tester
Angus M Tester
APAlberto M. Pendás
Alberto M. Pendás
APAna S Pitiot
Ana S Pitiot
CLCarlos López-Otín
Carlos López-Otín

28 March 2007 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
AGAna Gutiérrez-Fernández
Ana Gutiérrez-Fernández
MIMasaki Inada
Masaki Inada
MBMilagros Balbín
Milagros Balbín
AFAntonio Fueyo
Antonio Fueyo
APAna S. Pitiot
Ana S. Pitiot
XPXose S. Puente
Xose S. Puente
Matrix metalloproteinases (MMPs) have been implicated in numerous tissue‐remodeling processes. The finding that mice deficient in collagenase‐2 (MMP‐8) are more susceptible to develop skin cancer, prompted us to investigate the role of this protease in cutaneous wound healing. We have observed a significant delay in wound closure in MMP8 −/− mice and an altered inflammatory response in their wounds, with a delay of neutrophil infiltration during the first days and a persistent inflammation at later time points. These changes were accompanied by alterations in the TGF‐β1 signaling pathway and by an apoptosis defect in MMP8 −/− mice. The delay in wound healing observed in MMP8 −/− mice was rescued by bone marrow transplantation from wild‐type mice. Analysis of other MMPs showed that MMP8 −/− mice had a significant increase in the expression of MMP‐9, suggesting that both proteases might act coordi‐nately in this process. This possibility was further supported by the novel finding that MMP‐8 and MMP‐9 form specific complexes in vivo. Taken together, these data indicate that MMP‐8 participates in wound repair by contributing to the resolution of inflammation and open the possibility to develop new strategies for treating wound healing defects.—Gutierrez‐Fernandez, A., Inada, M., Balbín, M., Fueyo, A., Pitiot, A. S., Astudillo, A., Hirose, K., Hirata, M., Shapiro, S. D., Noel, A., Werb, Z., Krane, S. M. Lopez‐Otín, C., Puente, X. S. FASEB J. 21, 2580–2591 (2007)

17 May 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PBPilar Blay
Pilar Blay
ISIñigo Santamaría
Iñigo Santamaría
APAna S Pitiot
Ana S Pitiot
MLMaría Luque
María Luque
MAMarta G Alvarado
Marta G Alvarado
MBMilagros Balbín
Milagros Balbín
The prevalence of BRCA1 and BRCA2 mutations in Spain is heterogeneous and varies according to geographical origin of studied families. The contribution of these mutations to hereditary breast and ovarian cancer has not been previously investigated in Asturian populations (Northern Spain). In the present work, 256 unrelated high-risk probands with breast and/or ovarian cancer from families living in Asturias were analyzed for the presence of a BRCA1 or BRCA2 gene mutation from October 2007 to May 2012. The entire coding sequences and each intron/exon boundaries of BRCA1/2 genes were screened both by direct sequencing and Multiplex Ligation-dependent Probe Amplification (MLPA). A total of 59 families (23%) were found to carry a pathogenic germ line mutation, 39 in BRCA1 and 20 in BRCA2. Twenty nine additional families (12%) carried an unknown significance variant. We detected 28 distinct pathogenic mutations (16 in BRCA1 and 12 in BRCA2), of which 3 mutations in BRCA1 (c.1674delA, c.1965C>A and c.2900_2901dupCT) and 5 in BRCA2 (c.262_263delCT, c.2095C>T, c.3263dupC, c.4030_4035delinsC, c.8042_8043delCA) had not been previously described. The novel mutations c.2900_2901dupCT in BRCA1 and c.4030_4035delinsC in BRCA2 occurred in 8 and 6 families respectively and clustered in two separated small geographically isolated areas suggesting a founder effect. These 2 mutations, together with the Galician BRCA1 mutation c.211A>G (9 families), and the common BRCA1 mutation c.3331_3334delCAAG (6 families), account for approximately 50% of all affected families. By contrast, very frequent mutations in other Spanish series such as the BRCA1 Ashkenazi founder mutation c.68_69delAG, was found in only one family. In this study we report the BRCA1 and BRCA2 spectrum of mutations and their geographical distribution in Asturias, which largely differ from other areas of Spain. Our findings may help design a first step recurrent mutation panel for screening high-risk breast and/or ovarian cancer families from this specific area.

21 February 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
LFLorena Fernández-Martínez
Lorena Fernández-Martínez
JRJosé Antonio Villegas Rubio
José Antonio Villegas Rubio
ÍSÍñigo Santamaría
Íñigo Santamaría
APAna S. Pitiot
Ana S. Pitiot
MAMarta G. Alvarado
Marta G. Alvarado
MBMilagros Balbín
Milagros Balbín
DICER1 syndrome is a pediatric cancer predisposition condition causing a variety of tumor types in children and young adults. In this report we studied a family with two relatives presenting a variety of neoplastic conditions at childhood. Germ-line mutation screening of the complete coding region of the DICER1 gene in genomic DNA from the proband was performed. The presence of somatic DICER1 mutation and further alterations in driver genes was investigated in genomic DNA obtained from available tumor samples. A nonsense germ-line mutation in DICER1 causing a truncated protein at the IIIb domain level was identified segregating within a family including two affected relatives who developed in one case cystic nephroma and pleuropulmonary blastoma, and rhabdomyosarcoma and multinodular goiter in the other. Additional in trans DICER1 missense somatic mutations in the IIIb DICER1 domain were found both in the cystic nephroma and in the rhabdomyosarcoma, suggesting that neoplasms in this family might arise from the unusual two-hit mechanism for DICER-derived tumorigenesis in which after the presence of a truncated constitutive protein, a neomorphic DICER1 activity is somatically adquired. Additional genetic alterations, such as TP53 mutations, were identified in the rhabdomyosarcoma. Besides DICER1 loss of standard activity, oncogenic cooperation of other genes, as mutated TP53, may involve developing higher grade tumors within this syndrome. Given the broad clinical spectrum that may arise, genetic counseling and close surveillance must be offered to all family members at risk of DICER1 syndrome.

16 May 2011 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ICIrene Centeno
Irene Centeno
PBPilar Blay
Pilar Blay
ISIñigo Santamaría
Iñigo Santamaría
AAAurora Astudillo
Aurora Astudillo
APAna S Pitiot
Ana S Pitiot
MBMilagros Balbín
Milagros Balbín
Background: A subset of lung cancer patients harbour EGFR somatic mutations in their tumours and are candidates for treatment with EGFR tyrosine kinase inhibitors. In a few cases EGFR mutations have also been found in the germ line, suggesting a role in lung carcinogenesis. Objetives of this study were: 1) To analyze the EGFR gene mutations in a population diagnosed with lung adenocarcinoma from Northern Spain. 2) To determine the frequency of a new germ-line mutation found in our laboratory as well as the frequency in our population of three other EGFR germ-line mutations detected by other authors. 3) To determine whether the novel mutation detected may have a functional effect on the EGFR protein. Methods: Tumour DNA samples were obtained from frozen or paraffin embedded tumour tissues. Samples of DNA from peripheral blood cells were obtained from 912 individuals with lung cancer recruited from the CAPUA study [1, 2], 477 unrelated healthy donor individuals and 32 individuals with other types of cancer. EGFR gene exons 18 to 21 were studied by direct standard dideoxy sequencing. Specific mutations were determined either by direct sequencing or by specific RFLP analysis. Cell lines were transfected with EGFR-mutant plasmids and analysed by western blot with antibodies specific for total or phosphorylated-EGFR. Results: We found EGFR mutation in 12 of the 71 tumour samples (17%). One tumour contained two mutations. One mutation (p.R776G) was present as a germ line. Using an RFLP analysis, this mutation was not found in 954 alleles from healthy individuals studied, concluding that it is not a polymorphism. The mutation was not found either in genomic DNA from 912 lung cancer patients. Three additional EGFR germ-line mutations that were already described were not found in any of the studied samples. These observations show that EGFR mutated alleles are rare in the population. In vitro studies revealed that tyrosine autophosphorylation is enhanced in p.R776G-mutant EGFR when compared with wild-type EGFR. This enhanced autophosphorylation in the absence of ligand may be associated with a proliferative advantage. Conclusions: Germ-line mutations in EGFR are rare but may contribute to oncogenesis

5 April 2007 in Leukemia
Verified
Journal Article
Closed access
APA S Pitiot
A S Pitiot
ISI Santamaría
I Santamaría
OGO García-Suárez
O García-Suárez
ICI Centeno
I Centeno
AAAurora Astudillo
Aurora Astudillo
MBM Balbín
M Balbín